Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells

Cancer Immunology Immunotherapy

Volumn 47, Issue 3, 1998, Pages 143-148

  Shimizu, Motomu ^a   Takeda, Yasutaka ^b   Yagita, Hideo ^c   Yoshimoto, Takayuki ^b   Matsuzawa, Akio ^b  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

Antitumor activity; Apoptosis; CD95 (Fas Apo 1); CD95L; lpr

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; FAS LIGAND;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; EFFECTOR CELL; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HEPATOMA CELL; LYMPH NODE CELL; LYMPHOID CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; FAS LIGAND PROTEIN; IMMUNOTHERAPY, ADOPTIVE; LIVER NEOPLASMS; LYMPHOCYTES; LYMPHOPROLIFERATIVE DISORDERS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED MRL LPR; MICE, MUTANT STRAINS; SPLEEN; T-LYMPHOCYTES;

EID: 0031796621     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050514     Document Type: Article

References (33)

1. Adachi M, Watanabe-Fukunaga R, Nagata S (1993) Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 90:1756
2. Allen RD, Marshall JD, Roths JB, Sidman CL (1990) Differences defined by bone marrow transplantation suggest that lpr and gld are mutations of genes encoding an interacting pair of molecules. J Exp Med 172:1367
3. Andrews BS, Eisenberg RS, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, Murphy ED, Roths JB, Dixon FJ (1978) Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 148:1198
4. Chu JL, Ramos P, Rosendorff A, Nikolic-Žugic J, Lacy E, Matsuzawa A, Elkon KB (1995) Massive upregulation of the Fas ligand in lpr and gld mice: Implications for Fas regulation and the graft-versus-host disease-like wasting syndrome. J Exp Med 181:393
5. Cohen PL, Eisenberg RA (1991) Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferalive disease. Annu Rev Immunol 9:243
6. Fujiwara M, Kariyone A (1984) One-way occurrence of graft-vs-host disease in bone marrow chimeras between congenic MRE mice. Immunology 53:251
7. Fukuzawa M, Fujiwara H, Yoshioka T, Itoh K, Hamaoka T (1984) Effector cell analysis of tumor cell rejection in vivo in two syngeneic tumor systems exhibiting distinct in vitro cytotoxic mechanisms. Gann 75:912
8. Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth cell kill. J Immunol Methods 119:203
9. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P (1994) Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528
10. Kayagaki N, Yamaguchi N, Nagao K, Matsuo S, Maeda H, Okumura K, Yagita H (1997) Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci USA 94:3914
11. Lücking-Famira KM, Daniel PT, Möller P, Krammer PH, Debatin K-M (1994) Apo-1 (CD95) mediated apoptosis in human T-ALL engrafted in SCID mice. Leukemia 8:1825
12. cg, that complements the gld gene in induction of lymphadenopathy in the mouse. J Exp Med 171:519
13. Matsuzawa A, Kimura M, Muraiso T, Kominami R, Katagiri T (1991) Genotype-restricted lymphoproliferation in autoimmune lpr mice. Eur J Immunol 21:1535
14. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55
15. Nagata S, Suda T (1995) Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39
16. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806
17. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH, Fonlana A (1995) Local Fas APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 25:2253
18. Roths JB, Murphy ED, Eicher EM (1984) A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/ HeJ mice. J Exp Med 159:1
19. Shimizu M, Yoshimoto T, Nagala S, Matsuzawa A (1996) A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo. Biochem Biophys Res Commun 228:375
20. Shimizu M, Yamamoto A, Nakano H, Matsuzawa A (1996) Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells. Cancer Res 56:3731
21. + T cell-mediated cytotoxicity. J Immunol 152:1127
22. Suda T, Nagata S (1994) Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 179:873
23. Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the 1 as ligand, a novel member of the tumor necrosis factor family. Cell 75:1169
24. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969
25. Theofilopoulos AN, Balderas RS, Gozes Y, Aguado MT, Hang L, Morrow PR, Dixon FJ (1985) Association of lpr gene with graft-vs-host disease-like syndrome. J Exp Med 162:1
26. Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, Debatin K-M, Krummer PH (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301
27. + lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells. J Immunol 159:2599
28. Watanabe D, Suda T, Hashimoto H, Nagata S (1995) Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. EMBO J 14:12
29. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S (1992a) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314
30. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S (1992b) The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 148:1274
31. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A (1994) Anti-Fas Apo-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 94:954
32. Winn HJ (1961) Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol 86:228
33. Yonehara S, Ishi A, Yonehara M (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-retiulated with the receptor of tumor necrosis factor. J Exp Med 169:1747